Federal
Register Notices > Importers
>
Hospira, Inc.
FR Doc E7-21847 [Federal Register: November 7, 2007 (Volume 72, Number
215)] [Notices] [Page 62872] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr07no07-85]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a registration
under this section to a bulk manufacturer of a controlled substance in
schedule I or II and prior to issuing a regulation under 21
U.S.C. 952(a)(2) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations (CFR),
1301.34(a), this is notice that on October 1, 2007, Hospira, Inc., 1776 North
Centennial Drive, McPherson, Kansas 67460-1247 made application by renewal to
the Drug Enforcement Administration (DEA) to be registered as an importer of
Remifentanil (9739), a basic class of controlled substance listed in schedule
II.
The company plans to import Remifentanil for use in dosage form
manufacturing.
Any bulk manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic class of controlled substance may file
comments or objections to the issuance of the proposed registration and may,
at the same time, file a written request for a hearing on such application
pursuant to 21
CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC
20537, or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than
December 7, 2007.
This procedure is to be conducted simultaneously with and independent of
the procedures described in 21
CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice
published in the Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substance listed in schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-21847 Filed 11-6-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|